Neoprobe continues losses in Q2

Justine Varieur Cadet | | Health Imaging | Oncology Imaging
Neoprobe, a developer of oncological surgical devices, has reported an increase in net losses for its second quarter of fiscal 2009, which ended June 30.

As a result of significant non-cash accounting charges in the 2009 second quarter, the company reported a net loss of $15.2 million compared with a net loss of $1 million for the second quarter in 2008. Neoprobe said its loss from operations for this year’s second quarter was $928,000 compared with $454,000 for the previous year’s second quarter.

The Dublin, Ohio-based Neoprobe said its 2009 second quarter revenues were $1.8 million compared with $2.3 million for the second quarter of 2008. The company’s second quarter 2009 operating expenses were $2.2 million compared with $1.8 million for the second quarter of 2008.

Brent Larson, Neoprobe’s vice president of finance and chief financial officer, attributed any gains to its gamma device business.

Justine Varieur Cadet

Related Content

MRI guidance significantly reduces radiotherapy side effects compared to CT
Interventional procedure often as effective as surgery for difficult-to-treat liver cancer
AI tumor volume estimations could improve prostate cancer treatment strategies
MRI could be 'powerful tool' for guiding surgery decisions in patients with rectal cancer
Breast cancer only visible via MRI is often less aggressive
Breast cancer rates are on the rise, new report reveals

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.